BioMarin Pharmaceuticals Inc (BMRN) is a publicly traded Healthcare sector company. As of September 30, 2026, BMRN trades at $60.17 with a market cap of $11.59B and a P/E ratio of 156.07. BMRN moved +0.24% today. Year to date, BMRN is +0.93%; over the trailing twelve months it is +10.78%. Its 52-week range spans $49.26 to $73.51. Analyst consensus is strong buy with an average price target of $93.15. Rallies surfaces BMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for BMRN, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $60.17 |
| Market Cap | $11.59B |
| P/E Ratio | 156.07 |
| EPS | $0.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $73.51 |
| 52-Week Low | $49.26 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.41B |
| Net Income | $72.97M |
| Gross Margin | 76.12% |
22 analysts cover BMRN: 0 strong buy, 17 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $93.15.